CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide) Topical Gel for the Treatment of Acne Vulgaris Now Available in the U.S.
- First FDA-approved fixed-dose, once-daily triple-combination topical treatment for acne
- Statistically significant reductions in both inflammatory and non-inflammatory lesions compared to vehicle gel
- 50.0% of participants achieved treatment success with CABTREO versus 22.6% with the vehicle gel at week 12
- Common adverse reactions including application site reactions, pain, erythema, dryness, irritation, exfoliation, and dermatitis
Insights
The launch of CABTREO by Bausch Health's Ortho Dermatologics represents a significant advancement in the treatment of acne vulgaris, a condition affecting millions annually. The triple-combination therapy's approval and market introduction are likely to influence Bausch Health's market share in the dermatological sector, potentially increasing the company's revenue stream. The product differentiates itself by combining an antibiotic, retinoid and antibacterial agent in a once-daily application, which simplifies the treatment regimen for patients.
From a competitive standpoint, CABTREO's efficacy in reducing both inflammatory and non-inflammatory lesions, as evidenced by the Phase 3 studies, positions it favorably against existing treatments. The statistical significance of the results (P<0.001) underscores the treatment's potential to become a preferred option for healthcare providers. The market's response to the new treatment will depend on its adoption by dermatologists and the patient experience, factoring in the effectiveness and adverse reaction profile compared to other treatments.
The FDA approval of CABTREO Topical Gel is grounded in robust clinical data from Phase 3 trials, which demonstrated a clear superiority over the vehicle gel in treating acne. Achieving over 70% reduction in lesions and a 50% treatment success rate at week 12 is a notable clinical outcome. These results may lead to a strong value proposition for the product in the medical community.
However, the adverse reactions reported, such as application site reactions and dermatitis, although occurring in a small percentage of patients, will need to be monitored as the product reaches a broader population. Long-term safety data will be crucial in maintaining the product's market position and could impact Bausch Health's reputation and financial performance if post-market surveillance reveals concerns.
The acne treatment market is a substantial segment of the dermatology industry. The introduction of CABTREO as a once-daily treatment is likely to be well-received by both patients and healthcare providers due to its convenience. The market impact of CABTREO's launch will depend on several factors, including pricing strategy, insurance coverage, marketing effectiveness and competition from both branded and generic products.
Market penetration will require strategic positioning to highlight CABTREO's benefits over existing therapies. If Bausch Health manages to secure favorable formulary placements and insurance coverage, it could significantly drive sales volume. Conversely, if the product is priced too high or if insurers are reluctant to cover it, the uptake may be slower than anticipated. Monitoring the company's quarterly financials following the launch will provide insights into the product's market performance and its impact on Bausch Health's overall financial health.
LAVAL, QC / ACCESSWIRE / January 30, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its dermatology business, Ortho Dermatologics, today announced the U.S. launch of CABTREO™ (clindamycin, adapalene, benzoyl peroxide) Topical Gel,
"With today's launch of CABTREO, millions of Americans who suffer from acne each year have access to a new once-daily triple-combination topical acne treatment," Thomas J. Appio, Chief Executive Officer, said. "In many instances, acne treatment requires using multiple products and dosing regimens, which can pose a number of challenges for patients. CABTREO has the potential to simplify dosing with a once daily topical acne treatment regimen."
CABTREO Topical Gel is the first and only U.S. Food and Drug Administration-approved fixed-dose, once-daily triple-combination topical treatment for acne and offers three mechanisms of action, combining an antibiotic, retinoid and antibacterial, to provide a proven, safe and effective treatment.
The FDA approved CABTREO Topical Gel on Oct. 20, 2023, based on data from two multicenter, randomized, double-blind, vehicle-controlled Phase 3 studies that demonstrated CABTREO Topical Gel resulted in statistically significant reductions in both inflammatory and non-inflammatory lesions compared to vehicle. At week 12,
The most common adverse reactions (occurring in >
About Acne Vulgaris
Acne is the most common skin problem in the United States, which occurs when hair follicles become obstructed with sebum and skin cells, resulting in the formation of whiteheads, blackheads, or pimples on the face, forehead, chest, upper back and shoulders.1,2 Up to 50 million Americans have acne.2 Depending on its severity, acne can cause emotional distress and scar the skin.2
What is CABTREO?
CABTREO (clindamycin phosphate, adapalene and benzoyl peroxide) Topical Gel
IMPORTANT SAFETY INFORMATION
Do not use CABTREO if you have had an allergic reaction to clindamycin, adapalene, benzoyl peroxide, lincomycin, or any of the ingredients in CABTREO or have Crohn's disease, ulcerative colitis, inflammation of the colon (colitis), or severe diarrhea with antibiotic use.
Before using CABTREO, tell your healthcare provider about all your medical conditions, including if you: plan to have surgery, are pregnant or plan to become pregnant, are breastfeeding or plan to breastfeed, have other skin problems, including cuts, abrasions, sunburn, or eczema; or use other skin and topical acne products that may increase the irritation of your skin when used with CABTREO.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, herbal supplements, and if you take or use a medicine that contains erythromycin. CABTREO should not be used with products that contain erythromycin.
What should I avoid while using CABTREO?
- Avoid or limit your time in sunlight, including use of sunlamps or tanning beds during treatment with CABTREO as it can make you more sensitive, and you could get severe sunburn. Use sunscreen and wear clothes including a hat that covers the treated areas of your skin if you have to be in sunlight.
- Cold weather and wind may irritate skin treated with CABTREO.
- Avoid applying CABTREO to areas with skin problems including, cuts, abrasions, sunburned skin, or eczema.
- Avoid skin products that may dry or irritate your skin.
- Avoid the use of "waxing" as a hair removal method on skin treated with CABTREO.
What are the possible serious and most common side effects of CABTREO?
Tell your doctor right away if you experience side effects, including:
- Allergic reactions: Stop using CABTREO if you have hives, rash, severe itching, swelling of your face, eyes, lips, tongue or throat, trouble breathing, throat tightness, feeling faint, dizzy, or lightheaded.
- Inflammation of the colon (colitis): Stop using CABTREO if you have severe stomach (abdominal) cramps, watery diarrhea, or bloody diarrhea during treatment, and within several weeks after treatment with CABTREO.
- Sensitivity to sunlight. See "What should I avoid while using CABTREO".
- Skin irritation at the application site is common with CABTREO and may include redness, scaling, dryness, stinging, burning, itching, and swelling.
These are not all the possible side effects of CABTREO. Call your doctor for medical advice about side effects. You may report side effects to Bausch Health US, LLC at 1-800-321-4576 or FDA at 1-800-FDA- 1088 or www.fda.gov/medwatch
Please click here for full Prescribing Information, Patient Information and Instructions for Use.
About Ortho Dermatologics
Ortho Dermatologics is one of the largest prescription and aesthetic dermatology businesses dedicated to helping patients in the treatment of a range of conditions, including psoriasis, onychomycosis, actinic keratosis, acne, atopic dermatitis and other dermatoses. More information can be found at https://www.ortho-dermatologics.com.
About Bausch Health
Bausch Health Companies Inc. (NYSE/TSX:BHC) is a global diversified pharmaceutical company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals and eye health, through our controlling ownership interest in Bausch +Lomb. With our leading durable brands, we are delivering on our commitments as we build an innovative company dedicated to advancing global health. For more information, visit www.bauschhealth.com and connect with us on Twitter and LinkedIn.
Forward-Looking Statements
This news release may contain forward-looking statements about the future performance of Bausch Health which may generally be identified by the use of the words "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "subject to" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Actual results are subject to other risks and uncertainties that relate more broadly to Bausch Health's overall business, including those more fully described in Bausch Health's most recent annual report on Form 10-K and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference.
References
1. American Academy of Dermatology. (2020). Skin conditions by the numbers. Retrieved from https://www.aad.org/media/stats/conditions/skin-conditions-by-the-numbers. Accessed March13, 2023.
2. Mayo Clinic. (2020). Acne. Retrieved from https://www.mayoclinic.org/diseasesconditions/acne/symptoms-causes/syc-20368047. Accessed March 13, 2023.
Investor Contact:
ir@bauschhealth.com
(877) 281-6642 (toll free)
Media Contact:
Kevin Wiggins
corporate.communications@bauschhealth.com
(848) 541-3785
###
CABTREO™ is a trademark of Ortho Dermatologics' affiliated entities.
Ortho Dermatologics is a trademark of Ortho Dermatologics' affiliated entities.
© 2024 Ortho Dermatologics' affiliated entities.
CAB.0025.USA.24
SOURCE: Bausch Health Companies Inc.
View the original press release on accesswire.com
FAQ
What is the name of the topical gel announced by Bausch Health Companies Inc.?
What is the indication for the CABTREO topical gel?
What are the mechanisms of action of CABTREO?
What were the results of the Phase 3 studies for CABTREO?
What are the common adverse reactions associated with CABTREO?
